아세만난

비특이적 면역 자극제 / 항바이러스제

아세만난은 **알로에 베라(Aloe vera)**에서 유래한 수용성 복합 탄수화물 중합체입니다. 수의학에서는 주로 비특이적 면역 자극제로 사용됩니다. * **승인된 용도:** 개와 고양이의 섬유육종 외과적 치료 및 임상 관리 보조. * **허가 외/시험적 용도:** 고양이의 바이러스 감염(FeLV, FIV, FIP) 및 개의 유두종증에 시도된 바 있습니다. * **임상적 논란:** 수의학적 효능을 뒷받침하는 강력한 대조 임상 연구가 부족하여 전신적 사용은 여전히 논란의 여지가 있습니다. * **국소 사용:** 국소용 제제도 있으며, 상처 치유 시간을 단축할 가능성이 있습니다.

작용 기전: Acemannan functions as a non-specific immune system modulator. * **Cytokine Induction:** Induces increases in key pro-inflammatory and immunomodulatory cytokines, specifically **Tumor Necrosis Factor-alpha (TNF-α)**, **Interferon**, and **Interleukin-1 (IL-1)**. * **Cellular Response:** → Leads to increased lymphocytic infiltration and accumulation at injection sites, promoting a localized immune response against tumor cells or pathogens. * **Antiviral Activity:** Has demonstrated the ability to suppress HIV replication in tissue cultures, though in vivo antiviral efficacy in veterinary species remains unproven.

동물 종별 용량

Cats

Aid in treatment and management of fibrosarcoma · Recommended IP dose is 1 mg/kg. Recommended intralesional dose is 2 mg injected deep into each tumor mass. · IP / Intralesional · weekly · minimum of 6 treatments · Prior to use, reconstitute with 10 mL sterile diluent. 5-10 mins may be necessary for complete dissolution. Shake well. Use within 4 hours. When used as a prelude to surgery, continue until delineation, necrosis or maximum tumor enlargement occurs (usually 2-4 weeks). Surgical excision recommended immediately upon delineation.

Dogs

Aid in treatment and management of fibrosarcoma · Recommended IP dose is 1 mg/kg. Recommended intralesional dose is 2 mg injected deep into each tumor mass. · IP / Intralesional · weekly · minimum of 6 treatments · Prior to use, reconstitute with 10 mL sterile diluent. 5-10 mins may be necessary for complete dissolution. Shake well. Use within 4 hours. When used as a prelude to surgery, continue until delineation, necrosis or maximum tumor enlargement occurs (usually 2-4 weeks). Surgical excision recommended immediately upon delineation.

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

IPIntralesionalIVTopical

금기

Patients with demonstrated past severe hypersensitivity reactions to acemannan

이상반응

Hypersensitivity reactions
Localized necrosis at injection sites
Hyperactivity
Lethargy
Fever
Hypotension
Salivation (with IV bolus)
Weakness and collapse (with IV bolus)
Tachycardia and tachypnea (with IV bolus)
Prolonged pain or bleeding at intralesional injection sites
Monocyte infiltrates on peritoneal surfaces, liver, lung, and spleen (with IP injection)
Abdominal pain, diarrhea, and vomiting (with high-dose IP injection)

모니터링

Clinical efficacy (tumor delineation, necrosis, or reduction)
Adverse effects (especially localized injection site reactions, hypersensitivity, or systemic signs if given IV/IP)

과용량

Acemannan appears to have a wide margin of safety regarding acute toxicity. * **Dogs (IP):** Single IP injections of 50 mg/kg resulted in no significant signs of toxicity. * **Dogs (Oral):** Acemannan fed orally at rates of up to 1.5 g/kg/day for 90 days showed no significant adverse effects.

VetSheet 약물 레퍼런스는 면허 수의 전문가를 위한 임상 의사결정 보조 도구이며, 전문적 판단이나 제조사의 최신 라벨을 대신하지 않습니다.